Physician
Neurology
Dr. Karen L. Fink, MD
|
|
Give Review
Karen L. Fink, MD is an expert in the field of Neurology. She studied medicine at Mayo Medical School. Mayo Medical School has a rank of 27 in research and a 42 in primary care Karen Fink is also a published doctor. She has 28 publication published. The most recent publication is: Infrequency of p53 gene mutations in ependymomas. She accepts all Medicare patients.
Publications
- High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III Astrocytomas and oligoAstrocytomas.
- A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
- Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendroGliomas: radiation therapy oncology group trial...
- Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
- A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NAB...
- A North American Brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
- Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
- Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American Brain tumor consortium study.
- Progression-free survival: an important end point in evaluating therapy for recurrent high-grade Gliomas.
- Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
- Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american Brain tumor co...
- Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
- Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain ...
- Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncolo...
- A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
- Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
- Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
- Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
- Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Tr...
- Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
- Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
- O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic Gliomas.
- Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium s...
- A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
- A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
- Infrequency of p53 gene mutations in ependymomas.
Schools
Mayo Medical School
Mayo Grad School Med
University Tx Sw Med Center
Procedures Preformed
- EEG (Electroencephalogram)
- EMG (Electromyography)
Conditions Treated
- Ataxia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Aneurysm
- Brain Cancer
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Education
-
Mayo School of Graduate Medical Education -
Mayo Medical School
Hospital
-
Baylor University Medical Center
Drug Facts
| NPI NUMBER | 1417993841 | |
| NPPES Provider LastName | FINK | |
| NPPES Provider FirstName | KAREN | |
| NPPES Provider ZIPCode | 752461800 | |
| NPPES Provider State | TX | |
| Specialty Description | Neurology | |
| Total Claim Count | 790.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 25.0 | |
| Percent Opioid Claims | 3.16 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417993841 |
| Last Name Of The Provider | FINK |
| First Name Of The Provider | KAREN |
| View All |
Similar Doctors
|
|
Dr. Jeffrey L. Elliott, MD |
|
|
Dr. Steven A. Vernino, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mary M. Quiceno, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew S. Anderson, MD |
|
|
Dr. Lu Lin, MD
This Doctor is OpenDoctor Recommended.
|